ReviewFrontiers in immunology2026
Lipid metabolism: a potential checkpoint for cGAS-STING regulation in colorectal cancer.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Immunotherapy for colorectal cancer (CRC) continues to face significant challenges, particularly in patients with microsatellite stable (MSS) tumors. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is a key regulator of innate immunity and has emerged as a promising target for enhancing anti-tumor immune responses. Meanwhile, lipid metabolic reprogramming is a defining hallmark of CRC and contributes to tumor progression, evasion, and therapeutic resistance. Although direct evidence linking lipid metabolism to cGAS-STING signaling in CRC remains limited, accumulating studies from diverse disease models suggest extensive interactions between these two processes. This review summarizes the major features of lipid metabolic reprogramming in CRC and discusses current understanding of cGAS-STING signaling in tumor immunity. We further examine potential mechanisms by which lipid metabolism may influence cGAS-STING activity, including the regulation of mitochondrial DNA release, intracellular trafficking of signaling components and lipid-associated post-translational modifications. Emerging evidence also indicates that cGAS-STING signaling can affect lipid metabolic pathways by regulating lipid metabolic homeostasis and inducing lipid peroxidation-driven ferroptosis. Importantly, microbiota-derived lipid metabolites exert context-dependent effects on cGAS-STING signaling to balance intestinal inflammation and anti-tumor immunity. Finally, we discuss therapeutic strategies targeting lipid metabolism and cGAS-STING signaling, with a particular focus on approaches that may enhance anti-tumor immunity through coordinated metabolic-immune modulation. By bridging metabolic reprogramming with innate immune sensing, we propose that modulating the lipid-cGAS-STING axis could break immune tolerance and offer a distinct therapeutic window for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.